Considering that all patients with MMR deficiency had early-stage tumors, we further evaluated the prognostic impact of MMR deficiency in patients with early-stage tumors (Fig. 2D), but statistical significance was not achieved in terms of PFS. This evidence concerns the gene MRC1 and hyperinsulinemic hypoglycemia, familial, 4.